2-acetoxy-5-chlorobenzoyl chloride | 5538-53-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-acetoxy-5-chlorobenzoyl chloride
• 英文别名: (2-carbonochloridoyl-4-chlorophenyl) acetate
• CAS: 5538-53-4
• 化学式: C₉H₆Cl₂O₃
• 分子量: 233.051
• InChiKey: YQWHRHOJSFLPDD-UHFFFAOYSA-N

物化性质

• 沸点：
  318.1±32.0 °C(Predicted)
• 密度：
  1.408±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-acetoxy-5-chlorobenzoyl chloride 在 sodium hydroxide 作用下， 反应 12.0h， 生成 8-[(5-氯-2-羟基苯甲酰基)氨基]辛酸
  参考文献：
  名称：

  Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin

  摘要：

  A family of novel compounds (delivery agents) that promote the gastrointestinal absorption of USP heparin in rats and primates has been discovered. The delivery agents in combination with heparin were administered either orally or intracolonically in an aqueous propylene glycol solution and caused dramatic increases in both plasma heparin concentrations (anti-Factor Xa) and clotting times (APTT). Using one of the most effective delivery agents in this series, an estimated relative bioavailability of 8% can be achieved following oral administration to cynomolgus monkeys. To establish a correlation between the in vivo data and an in vitro parameter, immobilized artificial membrane (IAM) chromatography was performed. Log relative k' values were correlated to the efficiency of oral heparin delivery.

  DOI：

  10.1021/jm970811m
• 作为产物：
  描述：

  5-氯代水杨酸 在 吡啶 、 氯化亚砜 、 磷酸 作用下， 生成 2-acetoxy-5-chlorobenzoyl chloride
  参考文献：
  名称：

  小檗碱9-O-苯甲酸衍生物的合成及抗氧化活性

  摘要：

  虽然小檗碱（BBR）具有抗氧化活性，但其活性有限。我们合成了 9 - O-苯甲酸小檗碱衍生物，并通过ABTS、DPPH、HOSC 和 FRAP 测定筛选了它们的抗氧化活性。苯甲酸环上的对位被卤素元素修饰，从而增强了抗氧化活性，并且发现邻位上的取代基优于间位。化合物8p , 8c , 8d , 8i , 8j , 8l , 尤其是8p显示出显着更高的抗氧化活性，这可归因于电子供体基团。所有小檗碱衍生物均具有适当的亲油性。总之，化合物8p是一种很有前途的抗氧化剂候选物，具有显着提高的抗氧化活性和中等的亲脂性。

  DOI：

  10.1039/d1ra01339d

文献信息

• BIS-AROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION
  申请人：Pelcman Benjamin

  公开号：US20100286215A1

  公开（公告）日：2010-11-11

  There is provided compounds of formula (I): wherein Y, ring A, D 1 , D 2 , D 3 , L 1 , Y 1 , L 2 , Y 2 , L 3 and Y 3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C 4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.

  提供了具有以下式（I）的化合物：其中Y、环A、D1、D2、D3、L1、Y1、L2、Y2、L3和Y3的含义如描述中所示，并且其药学上可接受的盐，这些化合物在治疗需要或者期望抑制白三烯C4合酶的疾病中非常有用，特别是在治疗呼吸道疾病和/或炎症方面。
• Synthesis and Biological Activity of Novel 1,3-Benzoxazine Derivatives as K+ Channel Openers.
  作者：Satoshi YAMAMOTO、Shohei HASHIGUCHI、Shokyo MIKI、Yumiko IGATA、Toshifumi WATANABE、Mitsuru SHIRAISHI

  DOI：10.1248/cpb.44.734

  日期：——

  A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant

  设计了一系列在C4处带有2-吡啶1-氧化物基团的1,3-苯并恶嗪衍生物新系列，以探索新型的K +通道开放剂。通过使用亚氨基三氟甲磺酸的钯（0）催化的碳-碳键形成反应与有机锌试剂进行合成，并通过新的一锅一锅的苯甲酰基吡啶的1,3-苯并恶嗪骨架形成反应进行合成。测试了这些化合物在四乙基氯化铵（TEA）中的血管舒张活性，以及​​BaCl2诱导的和高KCl诱导的大鼠主动脉收缩，以确定潜在的K +通道开放剂，以及在自发性高血压大鼠中的口服降压作用。1,3-苯并恶嗪核的C6处具有适当形状的吸电子基团和C7处具有甲基或卤代基团是开发最佳血管舒张剂和降血压活性所必需的。特别是，
• Imidazolyl derivatives of the chroman ring 3
  作者：Paolo Cozzi、Antonio Pillan

  DOI：10.1002/jhet.5570230618

  日期：——

  zol-2-yl)-4H-1-benzopyran-4-ones 4 is described starting from 2-acetoxybenzoyl chlorides and 1,2-dimethylimidazole. Chromones 4 undergo alkaline ring opening to the corresponding 1-(2-hydroxyphenyl)-2-(1-methyl-1H-imidazol-2-yl)ethenols 5 which give ring closure to 2-substituted 3-(1-methyl-1H-imidazol-2-yl)-4H-1-benzopyran-4-ones or 2,3-dihydro-3-(1-methyl-1H-imidazol-2-yl)-4H-1-benzopyran-4-ones

  2-甲基-3-（1-甲基- 1的合成ħ咪唑-2-基）-4- ħ -1-苯并吡喃-4-酮4中描述了从2-乙酰氧基苯甲酰基氯化物和1,2-二甲基咪唑开始。染色体4对相应的1-（2-羟苯基）-2-（1-甲基-1 H-咪唑-2-基）乙烯醇5进行碱性开环，这些环使2取代的3-（1-甲基- 1 H-咪唑-2-基）-4 H -1-苯并吡喃-4-酮或2,3-二氢-3-（1-甲基-1 H-咪唑-2-基）-4 H -1-苯并吡喃-4-ones。可以从色酮4容易地获得相应的色醇和色烯。
• Design, Synthesis and Activity Evaluation of N-(pyridin-4-yl) Salicylamides as Antimycobacterial Agents
  作者：He Dian、De-Bin Zhou、Jian-Ping Mou、Zhu-Qing Yang、Jia Zhong、Xiao-Quan Ding、Chong Li、Xiao-Hong Wang、Jian-Gang Zhang

  DOI：10.14233/ajchem.2014.16594

  日期：——

  A series of N-(pyridin-4-yl) salicylamides derivatives were prepared through acylation of the corresponding acetylsalicyloyl chlorides with substituted 4-amino-pyridines. These compounds were evaluated in vitro for antimycobacterial activities against Mycobacterium tuberculosis (TB) and Mycobacterium avium (A) by the minimum inhibitory concentrations (MIC) values. Eight of the compounds exhibited lower MIC against A than the one of isoniazide. Meanwhile, four of the compounds exhibited good anti-TB activity compared to isoniazide. Antimycobacterial activities of N-(pyridin-4-yl) salicylamides were influenced by the balance between hydrophobicity and electron withdrawing substituent effects on the phenyl and pyridine ring. These studies show that the compounds might serve as prospective wide-spectrum antimycobacterial substances.

  一系列N-(吡啶-4-基)水杨酰胺衍生物通过相应的乙酰水杨酰氯与取代的4-氨基吡啶的酰化反应制备而成。这些化合物通过最低抑制浓度（MIC）值在体外评估了对结核分枝杆菌（TB）和鸟分枝杆菌（A）的抗分枝杆菌活性。其中八种化合物的MIC值对A型菌低于异烟肼，同时有四种化合物表现出较异烟肼更强的抗TB活性。N-(吡啶-4-基)水杨酰胺的抗分枝杆菌活性受到苯环和吡啶环上的疏水性和电子吸引取代基效应之间平衡的影响。这些研究表明，这些化合物可能作为有前景的广谱抗分枝杆菌药物。
• [EN] COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES ET LEUR SYNTHÈSE
  申请人：UNIV NORTH CAROLINA

  公开号：WO2014165816A1

  公开（公告）日：2014-10-09

  The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

  本发明提供了式(I)化合物：其中变量X、Y、Z和R1如本文所述。本文所述的一些化合物是谷氨酸脱氢酶激活剂。本发明还涉及包含这些化合物的药物组合物、这些化合物和组合物在治疗代谢紊乱中的用途以及这些化合物的合成。